HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester

a soluble epoxide hydrolase inhibitor; structure in first source

Also Known As:

AUDA-BE

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - 12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester: 2
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Adamantane: 182
        12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester: 2
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester: 2

Experts

1.	Alkayed, Nabil J: 2 articles (11/2008 - 12/2007)
2.	Cao, Zhiping: 1 article (11/2008)
3.	Iliff, Jeffrey: 1 article (11/2008)
4.	Liu, Lijuan: 1 article (11/2008)
5.	Merkel, Matthias J: 1 article (11/2008)
6.	Motoki, Atsuko: 1 article (11/2008)
7.	Packwood, William H: 1 article (11/2008)
8.	Van Winkle, Donna M: 1 article (11/2008)
9.	Falck, John R: 1 article (12/2007)
10.	Grafe, Marjorie: 1 article (12/2007)

Related Diseases

1.	Ischemia 12/01/2007 - "However, regional CBF rates measured by iodoantipyrine (IAP) autoradiography at end ischemia revealed no differences between AUDA-BE- and vehicle-treated mice. " 11/01/2008 - "Wild-type mice were injected intraperitoneally with 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE), a sEH inhibitor, 30 min before LCA occlusion or during ischemia 10 min before reperfusion. "
2.	Stroke (Strokes) 12/01/2007 - "We determined expression and distribution of sEH immunoreactivity (IR) in brain, and examined the effect of sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE) on CBF and infarct size after experimental stroke in mice. "
3.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/01/2007 - "Mice were administered a single intraperitoneal injection of AUDA-BE (10 mg/kg) or vehicle at 30 mins before 2-h middle cerebral artery occlusion (MCAO) or at reperfusion, in the presence and absence of P450 epoxygenase inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl) hexanamide (MS-PPOH). "
4.	Infarction (Infarctions) 12/01/2007 - "Finally, AUDA-BE significantly reduced infarct size at 24 h after MCAO, which was prevented by MS-PPOH. " 12/01/2007 - "We determined expression and distribution of sEH immunoreactivity (IR) in brain, and examined the effect of sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE) on CBF and infarct size after experimental stroke in mice. "

Related Drugs and Biologics

1.	Esters
2.	Acids
3.	N- methylsulfonyl- 6- (2- propargyloxyphenyl)hexanamide
4.	iodoantipyrine
5.	caproamide

Related Therapies and Procedures

1.	Intraperitoneal Injections